Does myo-inositol oxygenase, the only enzyme to catalyze myo-inositol in vivo, play a role in the etiology of polycystic ovarian syndrome?. (4th May 2018)

• Record Type: Journal Article
• Authors: Mertoglu, Cuma; Gunay, Murat; Gul, Vahdet; Kulhan, Mehmet; Aktas, Mehmet; Coban, Taha Abdulkadir
• Is Part Of: Gynecological endocrinology. Volume 34:Number 5(2018)
• Page Start: 418
• Page End: 421
• Publication Date: 2018-05-04
• Subjects: Myo-inositol oxygenase -- polycystic ovarian syndrome -- myo-inositol -- inositol -- d-Chiro-inositol; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2017.1409710
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: In polycystic ovary syndrome (PCOS), myo-inositol (MI) supplements have shown many beneficial effects. In this study, therefore, we aimed to investigate the serum level of myo-inositol oxygenase (MIOX), which is the only enzyme catalyzing MI in vivo, in patients with PCOS. Serum MIOX enzyme levels and other laboratory parameters were compared between sixty patients, who were diagnosed with PCOS for the first time, and sixty healthy individuals at similar age and sex. MIOX serum levels were not different between two groups ( p = 0.7428). MIOX median and 95% CI were 19.4 and 10.6–39.1 in the control group and 16.4 and 7.6–46.2 in the patient group respectively. Demographic data, biochemical and hematological parameters, hormone parameters were not different except from the lymphocyte count between the two groups. Lymphocyte count was higher in the patient group. Although the ratio of LH/FSH was higher in the patient group, it was not statistically significant. Our results suggest that serum MIOX levels do not change in PCOS. It was, therefore, concluded that MI deficiency observed in PCOS was not related to the level of MIOX enzyme which cleaves MI.